Vitality Watch

Dossier clinicaltrials trial late 20-jul-2026
Large or late-phase randomized human trial

Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer’s Disease

Key claim: A 700-person RCT will test whether the Brain Safe consumer app reduces older adults’ exposure to strong anticholinergic drugs linked to Alzheimer’s disease risk versus an attention-control medication-list app.

Abstract

This study is an RCT to evaluate the effectiveness of Brain Safe on reducing anticholinergic exposure. Over 42 months, the trial will enroll 700 community-dwelling older adults who were prescribed one or more strong anticholinergics. Participants will be randomized to use the Brain Safe app or an attention control medication list app for 12 months, with monthly usage reminders.

Why this matters

Anticholinergic burden is one of the better-documented modifiable dementia-risk exposures, and Brain Safe is a rare case of a consumer app being tested at RCT scale rather than shipped on mechanism alone. The trend worth tracking is deprescribing moving into the direct-to-consumer app layer; the evidence question — whether a reminder app actually shifts prescriptions or outcomes — remains open pending readout.

Source

Link

Briefing card

Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer's Disease
Stage: trial late · clinicaltrials · 20-jul-2026

If you or an older adult you care for takes strong anticholinergic medications, this trial is testing whether a consumer app can help reduce that exposure — results are not yet available.

A 700-person RCT will test whether the Brain Safe consumer app reduces older adults’ exposure to strong anticholinergic drugs linked to Alzheimer’s disease risk versus an attention-control medication-list app.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT04121858

build build 880 · 2bcef25 · 2026-11-18